Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis.
carbamazepine
epilepsy
levetiracetam
neurocysticercosis
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
05
2020
revised:
03
09
2020
accepted:
24
09
2020
pubmed:
3
10
2020
medline:
7
4
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
The choice of antiepileptic drug (AED) in newly diagnosed neurocysticercosis (NCC) patients with epilepsy continues to be arbitrary. We compared efficacy and side effect profile of levetiracetam (LEV) and carbamazepine (CBZ) for the treatment of seizures in newly diagnosed patients with NCC. This was an open-labeled randomized comparative monotherapy study including newly diagnosed drug naïve patients of NCC (n = 99) presenting with seizures who were randomized in 1:1 ratio using computed generated numbers. All patients were followed up for at least six months after start of treatment. The primary outcome measure was seizure control over six months following start of AEDs. Fifteen (15.2%) patients [CBZ- 4(8.2%); LEV- 11(22%)] developed recurrence of seizures. A trend (p = 0.09) was found toward better control of seizures in CBZ compared to LEV. Two (4%) patients in LEV group and 17 (34.6%) patients in CBZ group developed drug-related minor side effects (p < 0.0001). Three patients in CBZ group needed discontinuation of therapy due to skin rash. Eleven patients who relapsed while on LEV did not have any recurrence of seizures after switching over to CBZ. Out of 3 patients who relapsed while receiving CBZ and were changed to LEV, two developed seizures during follow-up. CBZ and LEV could be used as alternatives in newly diagnosed patients of NCC at the behest of minor side effects in the CBZ group.
Sections du résumé
BACKGROUND
BACKGROUND
The choice of antiepileptic drug (AED) in newly diagnosed neurocysticercosis (NCC) patients with epilepsy continues to be arbitrary. We compared efficacy and side effect profile of levetiracetam (LEV) and carbamazepine (CBZ) for the treatment of seizures in newly diagnosed patients with NCC.
PATIENTS AND METHODS
METHODS
This was an open-labeled randomized comparative monotherapy study including newly diagnosed drug naïve patients of NCC (n = 99) presenting with seizures who were randomized in 1:1 ratio using computed generated numbers. All patients were followed up for at least six months after start of treatment. The primary outcome measure was seizure control over six months following start of AEDs.
RESULTS
RESULTS
Fifteen (15.2%) patients [CBZ- 4(8.2%); LEV- 11(22%)] developed recurrence of seizures. A trend (p = 0.09) was found toward better control of seizures in CBZ compared to LEV. Two (4%) patients in LEV group and 17 (34.6%) patients in CBZ group developed drug-related minor side effects (p < 0.0001). Three patients in CBZ group needed discontinuation of therapy due to skin rash. Eleven patients who relapsed while on LEV did not have any recurrence of seizures after switching over to CBZ. Out of 3 patients who relapsed while receiving CBZ and were changed to LEV, two developed seizures during follow-up.
CONCLUSION
CONCLUSIONS
CBZ and LEV could be used as alternatives in newly diagnosed patients of NCC at the behest of minor side effects in the CBZ group.
Substances chimiques
Anticonvulsants
0
Carbamazepine
33CM23913M
Levetiracetam
44YRR34555
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
242-247Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Del Brutto OH, Rajshekhar V, White AC, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology. 2001;57(2):177-183.
Del Brutto OH. Neurocysticercosis. Handb Clin Neurol. 2014;121:1446-2159.
Sharma M, Singh T, Mathew A. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev. 2015;3:1550-1555.
Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day (-1) in adult patients with refractory epilepsy. Seizure. 2008;12(2):141-149.
García HH, Evans CAW, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15(4):747-756.
Al Khalili Y, Jain S.Carbamazepine Toxicity. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-2019 Apr 14.
Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997;38(4):859-880.
Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68(20):1701-1709.
Valencak J, Ortiz-Urda S, Heere-Ress E, et al. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol. 2004;43(1):51-54.
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Acade. Neurology. 2018;91(2):74-81.
Murthy RS. National Mental Health Survey of India 2015-2016. Indian J Psychiatry. 2017;59(1):21-26.
Saxena S, Chaudhary A, Bansal N, et al. Neurocysticercosis. IOSR-J Dental Mental Sci. 2016;15(1):2279-2285.
Carabin H, Ndimubanzi PC, Budke CM, et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Neg Trop Dis. 2010;34(2):246-252.
Goyal M, Chand P, Modi M, et al. Neurocysticercosis: An uncommon cause of drug-refractory epilepsy in North Indian population. Epilepsia. 2015;56(11):1747-1752.